• Sara Pilotto, Francesco Agustoni, Anna Maria Morelli, Federica Lobascio, Emanuele Cereda, Paolo Bironzo, Ilaria Trestini, Michele Milella, Silvia Novello, Paolo Pedrazzoli, and Riccardo Caccialanza.
• Medical Oncology, Department of Medicine, University of Verona Hospital Trust, Verona, Italy.
• Nutrition. 2022 Jun 1; 98: 111637.

AbstractAlthough there is substantial evidence on the impact of nutritional-status deterioration on quality of life, treatment tolerance, morbidity, and mortality in people with cancer, clinical nutrition intervention trials in oncology are still limited. The rationale for deepening this topic is also justified by the availability of innovative treatment options, such as immunotherapy, which take into consideration potential modulation of the immune system by several factors. In this article, we aimed to focus on the unexplored issue of immunonutrition and its potential modulatory activity on treatment response in people receiving immunotherapy. With this perspective, we propose a clinical-trial model to explore the potential impact of immunonutrition on nutritional, functional, immunologic, safety, and efficacy parameters in people with advanced non-small cell lung cancer undergoing first-line immunotherapy-based anticancer treatment.Copyright © 2022 Elsevier Inc. All rights reserved.

15 keywords...

hide…